Mineralys Therapeutics (MLYS) said Monday that lorundrostat met primary endpoints in phase 3 Launch-HTN and phase 2 Advance-HTN trials in patients with uncontrolled hypertension or resistant hypertension.
Shares surged 73% as intraday trading volume soared to more than 12.4 million from a daily average of about 283,000.
Rocket (RKT) said Monday it will buy real-estate brokerage Redfin (RDFN) for an equity value of $1.75 billion to drive users to its home-lending business.
Shares of Redfin soared 65% as intraday trading volume catapulted to more than 81.1 million from a daily average of about 5.5 million.
Protagonist Therapeutics (PTGX) and Johnson & Johnson (JNJ) said a phase 2b study of the investigational targeted oral peptide icotrokinra in adults with moderately to severely active ulcerative colitis met the primary endpoint of clinical response in three dose levels at week 12, with a "favorable" safety profile.
Shares of Protagonist advanced 45%, with intraday trading volume rising to over 3.9 million compared with a daily average of about 725,000.
Price: 18.23, Change: +7.71, Percent Change: +73.29
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。